

Corp. Off.: 502, Kanakia Atrium - 2,
Next to Courtyard Marriott Hotel,
Andheri Kurla Road, Andheri (East),
Mumbai - 400 093 (India)
Ph.: + 91 22 61933100 Fax : +91 22 61933114

14th August, 2019

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Kind Attn: General Manager-DCS

Scrip Code: 533543

Kind Attn: Head- Listing

Symbol: **BROOKS**

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:



We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 1st quarter ended 30th June, 2019. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, together with the Limited Review Report is attached.

This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**



(Jyoti Sancheti)
Company Secretary cum Compliance Officer
Membership No. F9639
Encl.: As Stated Above

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net

Website: www.brookslabs.net


Tel No : +91 1795 654001/02/03,

Fax No :+91 1795 236939

Unaudited Financial Results for the Quarter ended 30th June, 2019

(Rs. In Lakhs)

No	Particulars	Quarter Ended		Year Ended	
		30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
		Unaudited	Audited (Refer Note 4)	Unaudited	Audited
1	Income				
	(a) Revenue from operations	1,682.18	1,515.56	1,067.33	5,503.01
	(b) Other Income	6.88	245.60	31.26	287.76
	Total income	1,689.06	1,761.16	1,098.59	5,790.78
2	Expenses				
	(a) Cost of materials consumed	1,026.92	1,282.01	781.64	4,057.22
	(b) Change in inventories of finished goods, work-in-progress and stock-in-trade	78.00	(158.15)	70.00	(113.62)
	(c) Employees benefits expenses	318.20	360.60	270.41	1,216.43
	(d) Finance Costs	82.82	72.29	69.52	296.26
	(e) Depreciation and amortization expenses	157.21	160.61	162.93	649.96
	(f) Other expenses	271.60	273.66	306.07	1,179.31
	Total Expenses	1,934.75	1,991.02	1,660.57	7,285.56
3	Profit/(Loss) before exceptional items and tax	(245.69)	(229.86)	(561.98)	(1,494.78)
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) from ordinary activities before tax	(245.69)	(229.86)	(561.98)	(1,494.78)
6	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax Liability / (Assets) (Refer Note no.8)	127.72	464.38	(190.59)	(14.48)
	Short income tax provision for earlier years	-	-	-	0.23
7	Net Profit/(loss) after tax	(373.41)	(694.24)	(371.39)	(1,480.53)
8	Other Comprehensive Income				
	Items That will not be reclassified into Profit or loss				
	Actuarial loss on Defined Benefit plans (net of tax).	(2.46)	(7.72)	0.20	(7.11)
9	Total Comprehensive income for the period (After tax)	(375.86)	(701.96)	(371.19)	(1,487.63)
10	Paid - up equity share capital of Rs.10 each	1,618.64	1,618.64	1,618.64	1,618.64
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	9,828.59	-	9,828.59
12	Earnings per share of Rs.10/- each (not annualised):				
	(a) Basic	(2.31)	(4.29)	(2.29)	(9.15)
	(b) Diluted	(2.31)	(4.29)	(2.29)	(9.15)




Notes:

- 1 The above audited financial results of the Company for quarter ended 30th June, 2019 have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors in their respective meetings held on 14th August, 2019
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment. As the Company's business actually falls within a single primary business segment, the disclosure requirements of Ind-AS – 108 in this regard are not applicable.
- 4 The figures of the last quarter ended March 31, 2019 are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the financial year.
- 5 Comparative financial information of the previous quarter and financial year have been regrouped and reclassified, wherever necessary, to correspond to the figures of the current period presentation.

Place : Mumbai
Date : 14th August 2019

For and on Behalf of Board


Rajesh Mahajan
Din : 02000634
Managing Director



SGCO & Co.LLP

Chartered Accountants

Limited Review Report on Unaudited Quarterly Financial Results of Brooks Laboratories Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To The Board of Directors of


Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Brooks Laboratories Limited** (The "Company"), for the quarter ended 30th June, 2019. ("the Statement").

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended ("the Listing Regulations") Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SGCO & Co. LLP
Chartered Accountants
Firm Registration No. 112081W/W100184


Suresh Murarka
Partner



Mem No.: 044739
UDIN:19044739AAAAEG2205

Place: Mumbai
Date : 14th August 2019

4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai – 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail: info@sgco.co.in
www.sgco.co.in